Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Corporate Gp Vi Ltd. Qiming Sells 43,930 Shares of Stock

Alamar Biosciences, Inc. (NASDAQ:ALMR) major shareholder Corporate Gp Vi Ltd. Qiming sold 43,930 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $29.84, for a total transaction of $1,310,871.20. Following the sale, the insider owned 160,913 shares of the company’s stock, valued at approximately $4,801,643.92. This represents a 21.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

• On Friday, October 30th, Corporate Gp Vi Ltd. Qiming sold 143,706 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.38, for a total value of $4,365,788.28.
• On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The shares were sold at an average price of $32.77, for a total transaction of $3,304,428.49.
• On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The stock was sold at an average price of $31.39, for a total value of $2,664,822.66.
• On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.52, for a total value of $4,044,632.48.
• On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.59, for a total transaction of $4,525,301.06.
• On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.33, for a total value of $3,924,676.63.
• On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.31, for a total transaction of $6,329,182.65.
• On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total transaction of $3,960,491.56.
• On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The stock was sold at an average price of $26.34, for a total transaction of $1,988,880.72.
• On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.02, for a total transaction of $3,674.72.

Alamar Biosciences Price Performance

Shares of Alamar Biosciences stock traded up $1.28 during trading on Tuesday, reaching $30.22. 673,925 shares of the stock traded hands, compared to its average volume of 423,943. The firm has a market cap of $2.10 billion and a P/E ratio of -15.42. The firm’s fifty day moving average price is $30.54. The company has a debt-to-equity ratio of 0.03, a current ratio of 11.85 and a quick ratio of 10.23. Alamar Biosciences, Inc. has a 52-week low of $18.84 and a 52-week high of $39.61.

Alamar Biosciences (NASDAQ:ALMR) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. The firm had revenue of $33.55 million for the quarter. On average, research analysts predict that Alamar Biosciences, Inc. will post -1.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alamar Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of ALMR. China Universal Asset Management Co. Ltd. bought a new position in shares of Alamar Biosciences during the 3rd quarter valued at approximately $196,000. Squarepoint Ops LLC bought a new stake in Alamar Biosciences in the second quarter worth $283,000. Sumitomo Mitsui Trust Group Inc. lifted its position in Alamar Biosciences by 18.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock worth $2,280,000 after buying an additional 10,461 shares during the last quarter. State Street Corp purchased a new position in Alamar Biosciences during the second quarter worth $3,930,000. Finally, Wellington Management Group LLP purchased a new position in Alamar Biosciences during the second quarter worth $12,407,000.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ALMR. TD Cowen reissued a “buy” rating on shares of Alamar Biosciences in a report on Wednesday, July 15th. Weiss Ratings lowered shares of Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. JPMorgan Chase & Co. lifted their price objective on shares of Alamar Biosciences from $32.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. Finally, Stifel Nicolaus boosted their target price on shares of Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Alamar Biosciences presently has a consensus rating of “Hold” and an average price target of $31.80.

Alamar Biosciences Company Profile

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.